Showing 7881-7890 of 8822 results for "".
- Naked Eye, Smart Phone Apps May Miss Melanomashttps://practicaldermatology.com/news/naked-eye-smart-phone-apps-may-miss-melanomas/2457486/The naked eye alone is not enough to accurately diagnosis skin cancer and smart phone apps may also miss melanomas, according to a new review published in The Cochrane Library as part of a Special Collection of Coch
- Phase 3 Data Positive for Revance's RT002https://practicaldermatology.com/news/phase-3-data-positive-for-revances-rt002/2457489/Long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term safety study. Completion of this study paves the way for Revance Therapeutics, Inc. to subm
- Encore Dermatology Announces Phase 2 Safety Data for Impoyzhttps://practicaldermatology.com/news/encore-dermatology-announces-phase-2-safety-data-for-impoyz/2457496/A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temov
- Industry Vet Todd Zavodnick Joins Dermavent Sciences as CEOhttps://practicaldermatology.com/news/industry-vet-todd-zavodnick-joins-dermavent-sciences-as-ceo/2457506/Todd Zavodnick is the new Chief Executive Officer of Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences. "It is an honor to join Dermavant at such an exciting time in the company's growth," says Mr. Zavodnick in a news release. "Medical dermatology
- MDsave Partners with CareCredithttps://practicaldermatology.com/news/mdsave-partners-with-carecredit/2457505/MDsave is partnering with CareCredit to bring easy healthcare financing to their mission of providing better cost transparency to patients. As consumers face ever increasing healthcare costs, CareCredit, a Synchrony solution, offers patients the ability to pay over time for deductibles, co-pays,
- US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-grants-dupixent-priority-review-for-moderate-to-severe-ad-in-adolescents/2457517/The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with m
- Cooling Caps and Other Cooling Methods May Prevent Taxane-Induced Dermatologic Eventshttps://practicaldermatology.com/news/cooling-caps-and-other-cooling-methods-may-prevent-taxane-induced-dermatologic-events/2457523/Cooling therapies such as cold caps, scalp cooling systems, frozen gloves, and frozen socks may offer the best protection against the adverse effects of taxane-based chemotherapy, according to a new study in JAMA Dermatology. “Taxanes induce dermatologic changes through dir
- Researchers Identify Genes Involved in Skin Cancerhttps://practicaldermatology.com/news/researchers-identify-genes-involved-in-skin-cancer/2457528/Researchers at the Health Sciences department of the Universitat Jaume I (UJI) of Castellón, Spain, have identified the genes responsible for sun sensitivity and skin cancer vulnerability. The Skin Cancer Genetics and Human Pigmentation research group (Melanogén) has analysed the sk
- Actress Kristin Davis Partners with Coolsculpting for Denim Denial Programhttps://practicaldermatology.com/news/actress-kirstin-davis-partners-with-coolsculpting-for-denim-denial-program/2457532/"Sex and the City” star Kristin Davis is partnering with CoolSculpting for the new "Denim Denial" consumer program. Denim Denial recognizes that every woman has a pair of jeans on the top shelf of her closet or tucked away in a bottom drawer but is holding on to
- Ilumya Now Available for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-now-available-for-moderate-to-severe-plaque-psoriasis/2457534/Ilumya™ (tildrakizumab-asmn) 100mg/mL from Sun Pharmaceutical Industries Ltd. is now available in the United States. Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for s